The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 24, 2023

Filed:

Mar. 20, 2020
Applicant:

Sumitomo Pharma Oncology, Inc., Marlborough, MA (US);

Inventors:

David J. Bearss, Alpine, UT (US);

Stephen Patrick Anthony, Herber City, UT (US);

Michael Vincent McCullar, Walnut Creek, CA (US);

Susan Carol Smith, San Antonio, TX (US);

Assignee:

Sumitomo Pharma Oncology, Inc., Marlborough, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01N 43/04 (2006.01); A61K 31/70 (2006.01); A61K 31/453 (2006.01); A61P 35/02 (2006.01); A61K 9/00 (2006.01); A61K 31/7068 (2006.01);
U.S. Cl.
CPC ...
A61K 31/453 (2013.01); A61K 9/0019 (2013.01); A61K 31/7068 (2013.01); A61P 35/02 (2018.01);
Abstract

Provided herein are various regimens for treating acute myeloid leukemia (AML) in subjects (e.g, patients) who have undergone one or more prior anti-AML therapies involving venetoclax, and have shown disease progression after the one or more prior therapies. The treatment regimens disclosed herein involve alvocidib, either as a monotherapy, or in combination with cytarabine or a hypomethylating agent, such as decitabine or azacitidine. The treatment regimens disclosed herein do not involve combination therapy of alvocidib with venetoclax.


Find Patent Forward Citations

Loading…